SEC Form 4 · accession 0001209191-15-032907
Adamas Pharmaceuticals Inc · ADMS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Natalie McClure
Officer — SVP, Product Development
Period of report
Apr 6, 2015
Accepted (ET)
Apr 7, 2015 · 4:30 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001328143
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Apr 6, 2015 | M | 2,000 | $1.755 | A | 2,840 | D | |
| Common StockF1 | Apr 6, 2015 | S | 2,000 | $17.44 | D | 840 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2 | $1.755 | Apr 6, 2015 | M | 2,000 | D | — | Mar 3, 2020 | Common Stock | 2,000 | 16,666 | D |
Explanation of responses
- F1The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
- F2The Option shares vested according to the following schedule: one-fifth (1/5th) of the shares vest one year after January 4, 2010; the balance of the shares vest in a series of forty-eight (48)successive equal monthly installments measured from the first anniversary of January 4, 2010, subject to Reporting Person's Continuous Service (as defined in the Issuer's 2007 Stock Plan) as of each such date. The Option shares are subject to an early exercise right and may be exercised in full prior to vesting.